Back to Search Start Over

Effect of idebenone on bone marrow mesenchymal stem cells in vitro.

Authors :
Zhang, Jiahui
Zhang, Jun
Li, Tao
Zhang, Nannan
Tang, Shengnan
Tao, Zehua
Zhou, Xiaohe
Sun, Xiaochun
Chen, Huabiao
Source :
Molecular Medicine Reports. Apr2018, Vol. 17 Issue 4, p5376-5383. 8p. 5 Graphs.
Publication Year :
2018

Abstract

In recent years, stem cell research has continued to benefit from its crossover with chemistry, particularly the investigation of small molecular drugs modulating specific targets to regulate stem cell fate. Idebenone (IDB) is a yellow crystalline powder that is used in the treatment of chronic cerebrovascular diseases. The objective of the present study was to examine whether IDB had an influence on bone marrow‑derived mesenchymal stem cells (BMSCs) extracted from the bone marrow of Sprague‑Dawley rats. The effects of IDB on cell proliferation, cell cloning and migration were investigated. Cell cycle, apoptosis, DAPI nuclear staining and senescence‑associated β‑galactosidase (SA‑β‑gal) staining were also examined. The results revealed that IDB at suitable concentrations enhanced cell cloning capacity, promoted the proliferation of BMSCs, delayed cellular senescence, and inhibited cell apoptosis and migration. Western blot analysis indicated that IDB increased the expression of B‑cell lymphoma 2 (Bcl‑2), signal transducer and activator of transcription‑3, Nanog, octamer‑binding transcription factor 4, E‑cadherin, proliferating cell nuclear antigen, cyclinD1 and cyclinD3, and decreased the expression of Bcl‑2‑associated X protein, cleaved caspase‑3, N‑cadherin, vimentin and α‑smooth muscle actin. In conclusion, these experiments confirmed that IDB in low doses had no toxic effect and may exert protective effects on BMSCs. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
17912997
Volume :
17
Issue :
4
Database :
Academic Search Index
Journal :
Molecular Medicine Reports
Publication Type :
Academic Journal
Accession number :
128739267
Full Text :
https://doi.org/10.3892/mmr.2018.8506